Inogen, Inc.

NasdaqGS:INGN Rapport sur les actions

Capitalisation boursière : US$191.5m

Inogen Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de Inogen ont diminué à un taux annuel moyen de -17.5%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en à 10.1% par an. Les revenus ont augmenté de en à un taux moyen de 0.1% par an.

Informations clés

-17.55%

Taux de croissance des bénéfices

-16.53%

Taux de croissance du BPA

Medical Equipment Croissance de l'industrie8.90%
Taux de croissance des recettes0.11%
Rendement des fonds propres-11.83%
Marge nette-6.52%
Prochaine mise à jour des résultats07 May 2026

Mises à jour récentes des performances passées

Recent updates

INGN: Buybacks And New Leadership Will Support Future Returns

Analysts have adjusted their price target on Inogen to $12.00, reflecting updated views on revenue growth assumptions, profit margin expectations, and the valuation multiple following recently published Street research, including a positive initiation of coverage. Analyst Commentary Recent Street research on Inogen has combined a constructive long term narrative with a more restrained tone on execution risks and how much investors are currently being asked to pay for that story.

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Returns

Analysts have adjusted their price target on Inogen to $12.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, which keep the fair value view broadly in line with prior estimates. What's in the News Inogen appointed Jason Richardson as Chief Financial Officer, effective April 6, 2026, succeeding Michael Bourque, who will remain in an advisory role until June 30, 2026 (Key Developments).

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Earnings Power

Analysts have maintained their price target for Inogen at $12.00, making small adjustments to assumptions around the discount rate, revenue growth, profit margin, and future P/E, which together result in an unchanged fair value view. What's in the News Inogen approved a share repurchase program of up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with an expiry on the earlier of December 31, 2027, or when the full amount is used (Key Developments).

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Undervalued Upside

Analysts maintained their fair value estimate for Inogen at $13.00, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E that refine rather than significantly change their prior view. What's in the News Inogen announced a share repurchase program authorizing the company to buy back up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with the program running until the earlier of December 31, 2027, or when the full amount is used (Key Developments).

INGN: Sleep Therapy Portfolio Expansion Will Support Future Earnings Power

Analysts have adjusted their price target on Inogen to $12.00. The change reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.

INGN: Sleep Therapy Expansion Will Support Future Confidence In Undervalued Shares

Analysts have kept their price target for Inogen steady at US$13.00. This reflects only minor tweaks to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock.

INGN: Sleep Therapy Expansion Will Support Future Earnings Power Ahead

Narrative Update on Inogen Analysts have modestly adjusted their price target on Inogen to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. This has led to a refined valuation that still centers around a fair value of $12.00 per share.

INGN: Stable Guidance And New Respiratory Line Will Support Future Confidence

Analysts have kept their price target for Inogen broadly in line with prior views, with only a small adjustment supported by updated assumptions around discount rate, profit margin and future P/E expectations, rather than any major shift in the outlook. What's in the News Inogen launched Aurora CPAP masks as a new product line within its respiratory care portfolio, targeting patients with obstructive sleep apnea through the F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows range (Key Developments).

INGN: Rising Revenue Outlook Will Support Stronger Earnings Power Ahead

Analysts have raised their price target on Inogen by approximately $5 to around $12 per share, reflecting modestly higher expectations for revenue growth, profit margins, and future earnings multiples, despite a slightly higher assumed discount rate. What's in the News Issued new fourth quarter 2025 revenue guidance of $87 million to $90 million, implying roughly 10% year over year growth at the midpoint compared to fourth quarter 2024 (company guidance) Reiterated full year 2025 revenue outlook of $354 million to $357 million, targeting about 6% growth at the midpoint versus 2024 revenue (company guidance) Emphasized that the updated outlook reflects confidence in execution while maintaining a disciplined view of demand and pricing conditions in the portable oxygen concentrator market (company guidance) Valuation Changes The fair value estimate has risen materially, increasing from approximately $7.00 to $12.00 per share.

INGN: Guidance Stability Will Drive Confidence As Margins Poised To Improve

Analysts have maintained their price target for Inogen at $13.00. This reflects minimal changes in financial assumptions and a steady outlook for the company's revenue growth and profitability.

INGN: Profit Margins Will Strengthen As Revenue Guidance Remains Encouraging

Analysts have adjusted Inogen’s price target to $13.00. This is a slight change that reflects expectations of improved profit margins, despite modest revisions in growth rates and valuation metrics.

Slow Progress At Inogen ... But Progress All The Same

Nov 11

INGN: Profit Margins Will Strengthen Amid Broader Respiratory Care Market Expansion

Analysts have slightly increased their price target for Inogen to $13.00 per share. This change reflects modest adjustments to profit margin forecasts and discount rates in their updated models.

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Analysts have reaffirmed their price target for Inogen at $13.00, citing stable outlooks with only minor adjustments to key financial metrics. What's in the News Inogen issued new earnings guidance for the third quarter of 2025, projecting revenue between $91 million and $93 million.

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Analysts have raised their price target for Inogen from $11.00 to $13.00, citing updated projections of slightly stronger revenue growth and reduced discount rates as key contributors to the increased valuation. What's in the News Inogen, Inc.

There's No Escaping Inogen, Inc.'s (NASDAQ:INGN) Muted Revenues Despite A 29% Share Price Rise

Aug 31
There's No Escaping Inogen, Inc.'s (NASDAQ:INGN) Muted Revenues Despite A 29% Share Price Rise

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Despite an upward revision in revenue growth forecasts and a lower future P/E, the analyst consensus price target for Inogen has decreased from $11.67 to $11.00, indicating increased caution around the company’s fair value. What's in the News Inogen expects third quarter 2025 revenue of $91–93 million (~4% YoY growth) and full-year 2025 revenue of $354–357 million (~6% YoY growth).

Analysts Have Been Trimming Their Inogen, Inc. (NASDAQ:INGN) Price Target After Its Latest Report

May 10
Analysts Have Been Trimming Their Inogen, Inc. (NASDAQ:INGN) Price Target After Its Latest Report
User avatar

Yuwell Collaboration Will Open Chinese Respiratory Market

Strategic partnerships and product innovation in China and digital health are expected to drive growth and improve earnings potential.

Why Investors Shouldn't Be Surprised By Inogen, Inc.'s (NASDAQ:INGN) 35% Share Price Plunge

Mar 08
Why Investors Shouldn't Be Surprised By Inogen, Inc.'s (NASDAQ:INGN) 35% Share Price Plunge

A Volatile Share Price Masks Some Of The Progress At Inogen

Mar 01

Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Feb 28
Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 32%

Jan 22
Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 32%

Inogen: Upside Seems Limited After Big Move Up

Sep 24

Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Jul 16
Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Inogen: Improving, But Still Struggling For Air

Jul 01

Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

May 22
Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities

Apr 13

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Mar 01
Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Feb 01
Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Ventilation des recettes et des dépenses

Comment Inogen gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

NasdaqGS:INGN Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
31 Dec 25349-2316519
30 Sep 25347-2516620
30 Jun 25343-2616819
31 Mar 25340-2716919
31 Dec 24336-3617222
30 Sep 24332-5317422
30 Jun 24327-9217023
31 Mar 24322-9716822
31 Dec 23316-10217021
30 Sep 23328-13317020
30 Jun 23349-9617820
31 Mar 23369-9018222
31 Dec 22377-8418022
30 Sep 22366-5017921
30 Jun 22353-2817020
31 Mar 22351-2016718
31 Dec 21358-616217
30 Sep 213561115516
30 Jun 21337-214715
31 Mar 21307-513614
31 Dec 20308-613614
30 Sep 20313-213514
30 Jun 20331613613
31 Mar 203601414111
31 Dec 19362211429
30 Sep 19370321448
30 Jun 19373421487
31 Mar 19369461447
31 Dec 18358521347
30 Sep 18335411207
30 Jun 18309321076
31 Mar 1827626965
31 Dec 1724921885
30 Sep 1723727815
30 Jun 1722225765
31 Mar 1721224725
31 Dec 1620321695
30 Sep 1619219675
30 Jun 1617917645
31 Mar 1616813604
31 Dec 1515912574
30 Sep 151489534
30 Jun 151369493

Des revenus de qualité: INGN n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: INGN n'est actuellement pas rentable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: INGN n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 17.5% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de INGN au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: INGN n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Medical Equipment ( 7.5% ).

Rendement des fonds propres

ROE élevé: INGN a un retour sur capitaux propres négatif ( -11.83% ), car il n'est actuellement pas rentable.

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/04/30 18:50
Cours de l'action en fin de journée2026/04/29 00:00
Les revenus2025/12/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Inogen, Inc. est couverte par 9 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Anderson SchockB. Riley Securities, Inc.
Ilya ZubkovFreedom Broker
Matthew MishanKeyBanc Capital Markets Inc.